This article is more than 5 years old. Information may no longer be current.
Allegro completes enrollment in Luminate trial stage 2
Click Here to Manage Email Alerts
Allegro Ophthalmics has completed enrollment in the second stage of its DEL MAR phase 2b clinical trial of Luminate for patients with diabetic macular edema, according to a company press release.
In the first stage of the DEL MAR monotherapy trial, Luminate, a first-in-class integrin peptide therapy, met its primary and secondary endpoints; in this second stage, combined therapy with anti-VEGF treatment will be evaluated.
The 5-month, 75-patient, double-masked, placebo-controlled, randomized, multicenter trial is “designed to evaluate the safety and efficacy of intravitreal injections of Luminate 0.5 mg or 1.0 mg in combination with bevacizumab 1.25 mg and as an adjunctive therapy after treatment with a single treatment with bevacizumab 1.25 mg in patients with DME,” the release said.